Dayne Brown

Cooley advised Lexeo Therapeutics, a clinical-stage gene therapy company advancing gene therapy candidates for genetically defined cardiovascular diseases and a genetically defined subgroup of Alzheimer’s disease, on its approximately $100 million initial public offering.

Cooley advised MindMed, a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, on its successful proxy contest against FCM MM Holdings.

Cooley advised Exscientia, an AI-driven pharmatech company based in Oxford, United Kingdom, on its $510.4 million initial public offering, including concurrent private placements to SoftBank and the Bill & Melinda Gates Foundation. Partners David Boles, Claire Keast-Butler, Div Gupta and Marc Recht led the Cooley team advising Exscientia.

Cooley advised Vectiv Bio Holding on its $146.6 million initial public offering of 8,625,000 ordinary shares, which includes the full exercise of the underwriters’ option to purchase additional shares. VectivBio, whose securities now trade on the Nasdaq Global Market under the symbol “VECT,” is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need. Partners Div Gupta, Ryan Sansom and Brandon Fenn led the Cooley team.

Cooley advised Gamida Cell on its $75 million financing with Highbridge Capital Management. Partner Mischi a Marca led the Cooley team advising Gamida Cell, a cell therapy company working to develop cures for blood cancers and hematologic diseases.